Weight Loss Blend – SLU-PP-332 (250 mcg) / 5-Amino-1MQ (25 mg) / BPC-157 (125 mcg) x 90 Tablets

Overview

Weight Loss Blend combines three research compounds that have been independently studied for their influence on cellular energy, metabolic regulation, and tissue support. When paired together, SLU-PP-332, 5-Amino-1MQ, and BPC-157 create a synergistic formulation for exploring multiple pathways linked to mitochondrial activity, fat metabolism, and regenerative processes in preclinical models.

Components

SLU-PP-332

1. A synthetic small molecule classified as a pan-estrogen related receptor (ERRα, ERRβ, ERRγ) agonist.
2. Research indicates it promotes mitochondrial biogenesis, enhances aerobic-like metabolic activity, and supports oxidative energy pathways.
3. Preclinical findings suggest it may induce effects similar to endurance exercise at the cellular level, including increased muscle fiber adaptations and fat oxidation efficiency.

5-Amino-1MQ (5-Amino-1-methylquinolinium iodide)

1. A targeted inhibitor of nicotinamide N-methyltransferase (NNMT).
2. Inhibition of NNMT has been shown to raise NAD⁺ levels, a critical cofactor in cellular energy metabolism.
3. Preclinical studies report enhanced metabolic turnover, reduced fat storage, and improved muscle energy handling following administration in rodent models.

BPC-157 (Body Protection Compound-157)

1. A synthetic peptide fragment consisting of 15 amino acids, originally isolated from gastric protein sequences.
2. Known in research for its wide spectrum of biological activity, including angiogenesis promotion, tissue repair signaling, and cytoprotective effects.
3. Frequently studied in models of regeneration, inflammation control, and musculoskeletal recovery.

Chemical & Structural Details

1. SLU-PP-332: Small molecule ERR agonist, EC₅₀ for ERRα ≈ 98 nM. Molecular details remain proprietary, though structurally related to other mitochondrial modulators.
2. 5-Amino-1MQ: Quinolinium derivative with NNMT inhibitory activity. Formula commonly reported as C₁₁H₁₃IN₂.
3. BPC-157: Sequence Gly–Glu–Pro–Pro–Pro–Gly–Lys–Pro–Ala–Asp–Asp–Ala–Gly–Leu–Val. Molecular formula C₆₂H₉₈N₁₆O₂₂; molecular mass ~1,419.6 Da.

Areas of Preclinical Research

1. SLU-PP-332: Investigated for mitochondrial activation, fat oxidation, and exercise-mimicking gene expression in cell and animal models.
2. 5-Amino-1MQ: Studied for its impact on NAD⁺ homeostasis, energy balance, fat mass reduction, and glucose transporter expression in skeletal muscle.
3. BPC-157: Explored for its angiogenic, regenerative, and cytoprotective properties across models of injury, inflammation, and vascular health.

Citations

1. Focus Biomolecules – SLU‑PP‑332 (CAS 303760‑60‑3) acts as a pan-ERR agonist (ERRα EC₅₀ ≈98 nM) and enhances mitochondrial function and Type IIa fibers in muscle cell and rodent models. Molecular Structures – SLU‑PP‑332 / 5‑Amino‑1MQ / BPC‑157
2. PeptideBasics – 5‑Amino‑1MQ is an NNMT inhibitor that regulates fat metabolism and energy expenditure in preclinical metabolic studies. Molecular Structures – SLU‑PP‑332 / 5‑Amino‑1MQ / BPC‑157
3. PeptideResearchInstitute – 5‑Amino‑1MQ inhibits NNMT in aged mice, raises NAD⁺ levels, boosts metabolic rate, and supports muscle strength. Molecular Structures – SLU‑PP‑332 / 5‑Amino‑1MQ / BPC‑157
4. MDPI Pharmaceutics. 2025;18(2):185. “Multifunctionality and possible medical application of the BPC‑157 peptide.” Molecular Structures – SLU‑PP‑332 / 5‑Amino‑1MQ / BPC‑157